E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Post resusucitation disease after resuscitation from cardiac arrest |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10007515 |
E.1.2 | Term | Cardiac arrest |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029286 |
E.1.2 | Term | Neurologic disorder NOS |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059485 |
E.1.2 | Term | Therapeutic hypothermia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the impact of MgSO4 on time to achieving the target temperature with the ThermoSuit™ System. |
|
E.2.2 | Secondary objectives of the trial |
- To assess the ease and feasibility of implementing a therapeutic hypothermia protocol [including an externally applied LRS ThermoSuit™ (Life Recovery Systems HD, L.L.C., Kinnelon, NJ, USA) cooling system] to unconscious patients following resuscitation from an out-of-hospital or in-hospital cardiac arrest. - To evaluate the incidence of adverse events (total and serious) associated with the ThermoSuit™ in conjunction with the use of MgSO4 . - To evaluate the impact of MgSO4 on hemodynamics during and after the use of the ThermoSuit System. - To determine the duration a core target temperature range of 32-43°C is maintained before further interventions are required to avoid spontaneous re-warming. - To assess clinical (ICU and hospital mortality and length of stay (LOS), neurologic recovery at discharge) outcomes in patients treated with therapeutic hypothermia using the LRS ThermoSuit™. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Cardiac arrest prior to or during hospital admission, with restoration/return of spontaneous circulation (ROSC). 2. Estimated or known age > 18 years. 3. Intubation, ventilation and placement of esophageal temperature probe. 4. Persistent neurologic dysfunction i.e. comatose upon enrollment [GCS ≤ 8]. |
|
E.4 | Principal exclusion criteria |
1. Height greater than 188 cm. 2. Elbow-to-elbow width greater than 60 cm (as measured above the supine patient). 3. Core temperature less than 35°C after ROSC (as measured in the esophagus). 4. Comatose state before the cardiac arrest due to the administration of drugs that depress the central nervous system. 5. Known pregnancy. 6. Known terminal illness that preceded the arrest. 7. Known enrollment in another study of a device, drug, or biologic. 8. Major trauma or other co-morbidity requiring urgent surgery. 9. > 4 hours since return of spontaneous circulation. 10. Severe coagulopathy (with active bleeding). 11. Hemodynamic instability despite vasopressors (SBP < 90 mmHg or MAP < 60 mmHg for > 30 minutes after ROSC and before enrollment). 12. Bradycardia (HR<60/min) 13. Allergy against MgSo4 14. AV-block 15. Myasthenia gravis 16. Known terminal renal insufficiency (creatinine-clearence < 20ml/min) 17. Severe myocardial dysfunction (EF<25%) 18. Chronic digitalis therapy |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Cooling rate from start of cooling until a temperature of 34°C is reached as calculated by the formula: (Tempstart-34)/(Time34°C-Timestart) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of follow up of last patient (6 months after inclusion) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |